TN2011000381A1 - Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate - Google Patents

Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Info

Publication number
TN2011000381A1
TN2011000381A1 TN2011000381A TN2011000381A TN2011000381A1 TN 2011000381 A1 TN2011000381 A1 TN 2011000381A1 TN 2011000381 A TN2011000381 A TN 2011000381A TN 2011000381 A TN2011000381 A TN 2011000381A TN 2011000381 A1 TN2011000381 A1 TN 2011000381A1
Authority
TN
Tunisia
Prior art keywords
crystalline form
methyltetrazol
pyridin
fluorophenyl
dihydrogen phosphate
Prior art date
Application number
TN2011000381A
Other languages
English (en)
Inventor
Katharina Reichenbacher
Robert J Duguid
Jacqueline A Ware
D0Uglas Phillipson
Original Assignee
Trius Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289775&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trius Therapeutics filed Critical Trius Therapeutics
Publication of TN2011000381A1 publication Critical patent/TN2011000381A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
TN2011000381A 2009-02-03 2011-08-03 Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate TN2011000381A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14940209P 2009-02-03 2009-02-03
PCT/US2010/023122 WO2010091131A1 (fr) 2009-02-03 2010-02-03 Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one

Publications (1)

Publication Number Publication Date
TN2011000381A1 true TN2011000381A1 (en) 2013-03-27

Family

ID=42289775

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000381A TN2011000381A1 (en) 2009-02-03 2011-08-03 Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Country Status (29)

Country Link
US (6) US8426389B2 (fr)
EP (1) EP2393808B1 (fr)
JP (1) JP5584705B2 (fr)
KR (3) KR101918678B1 (fr)
CN (2) CN102439006A (fr)
AP (1) AP2987A (fr)
AU (1) AU2010210627B2 (fr)
BR (1) BRPI1008829A2 (fr)
CA (1) CA2751392C (fr)
CL (1) CL2011001855A1 (fr)
CO (1) CO6620071A2 (fr)
CR (1) CR20110464A (fr)
CU (1) CU24089B1 (fr)
DO (1) DOP2011000251A (fr)
EC (1) ECSP11011285A (fr)
ES (1) ES2734724T3 (fr)
IL (1) IL214401B (fr)
MA (1) MA33092B1 (fr)
MX (2) MX2011008093A (fr)
MY (1) MY156354A (fr)
NZ (3) NZ620458A (fr)
PE (1) PE20120585A1 (fr)
PH (1) PH12014500092A1 (fr)
RU (2) RU2655928C1 (fr)
SG (2) SG10201500207QA (fr)
TN (1) TN2011000381A1 (fr)
UA (1) UA114068C2 (fr)
WO (1) WO2010091131A1 (fr)
ZA (2) ZA201106412B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
ES2748505T3 (es) 2008-10-10 2020-03-17 Merck Sharp & Dohme Métodos para la preparación de oxazolidinonas y composiciones que las contienen
CU24089B1 (es) 2009-02-03 2015-04-29 Trius Therapeutics Forma cristalina del fosfato de dihidrógeno r)-3-(4-(2-(2-metiltretazol-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2013059610A1 (fr) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Polythérapie de daptomycine et d'un antibiotique inhibiteur de la synthèse protéique, et ses procédés d'utilisation
WO2015054246A1 (fr) * 2013-10-07 2015-04-16 Trius Therapeutics, Inc. Procédés de traitement de sujets présentant une insuffisance rénale à l'aide de tédizolid
CN105229001B (zh) * 2014-04-18 2017-04-26 杭州普晒医药科技有限公司 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途
WO2016009401A2 (fr) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Préparation du phosphate de tédizolid
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016063246A1 (fr) * 2014-10-22 2016-04-28 Sun Pharmaceutical Industries Limited Forme cristalline r de phosphate de tédizolide
WO2016088101A1 (fr) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Procédés de préparation de phosphate de tédizolide et de ses intermédiaires
WO2016088100A1 (fr) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Procédés pour préparer un phosphate de tédizolid et ses intermédiaires
WO2016088102A1 (fr) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Procédés pour la préparation de tedizolid et de ses intermédiaires
CZ306245B6 (cs) * 2014-12-11 2016-10-26 Univerzita Karlova v Praze Farmaceutická fakulta v Hradci Králové Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN106146485B (zh) * 2015-04-01 2021-04-30 上海迪赛诺化学制药有限公司 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN105085570B (zh) * 2015-09-12 2017-11-28 山东罗欣药业集团股份有限公司 一种磷酸特地唑胺化合物及其制备方法
CN105287407B (zh) * 2015-11-24 2018-09-21 南京正大天晴制药有限公司 一种注射用磷酸特地唑胺
CN107121503B (zh) * 2017-03-14 2020-04-28 南京优科制药有限公司 一种磷酸特地唑胺及其有关物质的分析方法
CN108948079A (zh) * 2017-05-17 2018-12-07 上海奥博生物医药技术有限公司 一种特地唑胺二铵盐及晶型与其制备方法
WO2019118311A1 (fr) * 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Compositions pharmaceutiques de tedizolid phosphate
IL299155A (en) 2020-06-18 2023-02-01 Akagera Medicines Inc Oxazolidinone compounds, liposome preparations containing oxazolidinone compounds and methods of using them
CN112957332B (zh) * 2021-02-04 2023-04-25 海南通用康力制药有限公司 注射用磷酸特地唑胺及其质量标准
CN112957333B (zh) * 2021-02-05 2022-11-22 海南通用康力制药有限公司 注射用磷酸特地唑胺及其制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) * 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (fr) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Derives d'aminomethyloxooxazolidinylaroylbenzene, agents antibacteriens
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5144911A (en) * 1990-11-28 1992-09-08 Moore Cheri L Component bed system for a pet
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
CZ288788B6 (cs) * 1992-12-08 2001-09-12 Pharmacia & Upjohn Company Antibakteriální fenyloxazolidinony substituované troponem
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
ATE182142T1 (de) 1993-11-22 1999-07-15 Upjohn Co Substituierte hydroxyacetyl piperazine phenyl oxazolidinonsäureester
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
CA2411859A1 (fr) * 2000-06-05 2001-12-13 Jae-Gul Lee Nouveaux derives oxazolidinone et processus de preparation de ces derives
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
DE60212959T2 (de) 2001-04-07 2007-02-15 Astrazeneca Ab Eine sulfonimid-gruppe enthaltende oxazolidinone als antibiotika
US6623140B2 (en) 2001-04-13 2003-09-23 Scott R. Watterson Illumination device having multiple light sources
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE60205030T2 (de) 2001-09-11 2006-04-20 Astrazeneca Ab Oxazolidinon- und/oder isoxazolinderivate als antibakterielle mittel
EP1446403B1 (fr) 2001-10-25 2006-04-12 AstraZeneca AB Oxazolidinones substituees par un groupe aryle presentant une activite antibacterienne
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
MXPA04008312A (es) * 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
BR0308018A (pt) 2002-02-28 2005-01-04 Astrazeneca Ab Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo
KR20050084010A (ko) * 2002-11-28 2005-08-26 아스트라제네카 아베 항균제로서의 옥사졸리디논
WO2004048392A1 (fr) * 2002-11-28 2004-06-10 Astrazeneca Ab Derives d'oxazolidinone et/ou d'isoxazoline utilises comme agents antibacteriens
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) * 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
AU2004256085B2 (en) * 2003-07-02 2007-12-06 Kyorin, Pharmaceutical Co., Ltd. Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
CA2530140C (fr) * 2003-07-02 2010-11-09 Merck & Co., Inc. Antibiotiques a base d'oxazolidinone substituee par un groupe cyclipropyl et derives
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
WO2005051933A1 (fr) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Procede ameliore de synthese d'ester test-butylique d'acide 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylique, compose intermediaire cle de la preparation d'agents antimicrobiens a l'oxazolidinone, et composes ainsi prepares
US7129259B2 (en) * 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US20080064689A1 (en) * 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
US20080021071A1 (en) * 2004-05-25 2008-01-24 Astrazeneca Ab 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
BRPI0511526A (pt) * 2004-05-25 2007-12-26 Astrazeneca Ab composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
AU2005247671A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as MAO inhibitors for the treatment of bacterial infections
EP1799677A1 (fr) 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Derives d'oxazolidinone utilises comme agents antimicrobiens
EP1912980A2 (fr) * 2005-06-20 2008-04-23 Wockhardt Limited Composition a activite antimicrobienne supportant des oxazolidinones ainsi que procedes de preparation associes
WO2007138381A2 (fr) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Oxazolidinones phosphonées et leurs utilisations pour la prévention et le traitement des infections des os et des articulations
EP2185549B1 (fr) * 2007-08-06 2018-10-03 Micurx Pharmaceuticals, Inc. Orthofluorophényle oxazolidinones antimicrobiennes pour le traitement d'infections bactériennes
CN101220001A (zh) * 2008-01-25 2008-07-16 浙江博泰化工有限公司 一种利奈唑酮的合成方法
ES2748505T3 (es) * 2008-10-10 2020-03-17 Merck Sharp & Dohme Métodos para la preparación de oxazolidinonas y composiciones que las contienen
CU24089B1 (es) 2009-02-03 2015-04-29 Trius Therapeutics Forma cristalina del fosfato de dihidrógeno r)-3-(4-(2-(2-metiltretazol-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Also Published As

Publication number Publication date
NZ712289A (en) 2017-03-31
SG173497A1 (en) 2011-09-29
WO2010091131A1 (fr) 2010-08-12
MX2011008093A (es) 2011-11-29
NZ620458A (en) 2015-10-30
CU20110155A7 (es) 2012-02-15
MA33092B1 (fr) 2012-03-01
RU2011136537A (ru) 2013-03-10
CN102439006A (zh) 2012-05-02
NZ594408A (en) 2014-03-28
US20170275315A1 (en) 2017-09-28
US20180244704A1 (en) 2018-08-30
MY156354A (en) 2016-02-15
AU2010210627A1 (en) 2011-08-25
CN107082790A (zh) 2017-08-22
EP2393808B1 (fr) 2019-05-08
CA2751392C (fr) 2017-03-28
US10442829B2 (en) 2019-10-15
AP2987A (en) 2014-09-30
RU2655928C1 (ru) 2018-05-30
US8426389B2 (en) 2013-04-23
ES2734724T3 (es) 2019-12-11
CU24089B1 (es) 2015-04-29
JP2012516894A (ja) 2012-07-26
BRPI1008829A2 (pt) 2016-03-15
IL214401B (en) 2021-03-25
US20160176905A1 (en) 2016-06-23
US20180251482A1 (en) 2018-09-06
CO6620071A2 (es) 2013-02-15
KR101918678B1 (ko) 2018-11-14
ZA201106412B (en) 2013-11-27
US20100227839A1 (en) 2010-09-09
PH12014500092B1 (en) 2014-12-01
PE20120585A1 (es) 2012-06-13
US20130310343A1 (en) 2013-11-21
AU2010210627B2 (en) 2016-03-03
AP2011005835A0 (en) 2011-08-31
CR20110464A (es) 2016-07-20
DOP2011000251A (es) 2011-11-15
US10065947B1 (en) 2018-09-04
US9988406B2 (en) 2018-06-05
CA2751392A1 (fr) 2010-08-12
PH12014500092A1 (en) 2014-12-01
EP2393808A1 (fr) 2011-12-14
IL214401A0 (en) 2011-09-27
ZA201306536B (en) 2014-05-28
UA114068C2 (xx) 2017-04-25
CL2011001855A1 (es) 2011-11-11
KR20110120311A (ko) 2011-11-03
MX2020011773A (es) 2020-11-24
JP5584705B2 (ja) 2014-09-03
ECSP11011285A (es) 2011-10-31
US9624250B2 (en) 2017-04-18
SG10201500207QA (en) 2015-03-30
KR20170040371A (ko) 2017-04-12
KR101739923B1 (ko) 2017-05-25
KR20170135984A (ko) 2017-12-08

Similar Documents

Publication Publication Date Title
PH12014500092A1 (en) Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
MX339597B (es) Derivados de oxazolidinona novedosos.
WO2009120789A8 (fr) Nitroimidazoles bicycliques liés par covalence à des phényloxazolidinones substituées
MA31928B1 (fr) Micro-organismes, fertilisants de phosphate microbien et procédés de préparation de ces fertilisants de phosphate microbien
NZ602311A (en) Anti-infective compounds
MX366793B (es) Metodos para preparar oxazolidinonas y composiciones que las contienen.
TW201713633A (en) Metallo-beta-lactamase inhibitors
EP1946760A4 (fr) Composition destinée à améliorer la flore intestinale
RU2010129158A (ru) Способ очистки мерзлотных почв от нефти спорообразующими бактериями bacillus subtilis
WO2014022382A3 (fr) Inhibiteurs de protéine kinase antibactérienne
NZ592168A (en) Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents
MY178871A (en) Methods of treating a pulmonary bacterial infection using fluoro-quinolones
MX2008000079A (es) Derivados de quinolina como agentes antibacterianos.
WO2011028492A3 (fr) Inhibiteurs de la sortase a
TH125050B (th) รูปแบบที่เป็นผลึกของ R)-3-(4-(2-(2-เมทธิลเตตราซอล-5-อิล)ไพริดิน-5-อิล)-3-ฟลูออโรฟีนิล)-5-ไฮดรอกซีเมทธิลออกซาโซลิดิน-2-โอน ไดไฮโดรเจนฟอสเฟต (R)-3-(4-(2-(2-Methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate)
TH125050A (th) รูปแบบที่เป็นผลึกของ R)-3-(4-(2-(2-เมทธิลเตตราซอล-5-อิล)ไพริดิน-5-อิล)-3-ฟลูออโรฟีนิล)-5-ไฮดรอกซีเมทธิลออกซาโซลิดิน-2-โอน ไดไฮโดรเจนฟอสเฟต (R)-3-(4-(2-(2-Methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate)
MX2010014248A (es) Nuevos antibioticos de trinem e inhibidores de beta-lactamasas.
WO2012096500A3 (fr) Composition probiotique destinée au bétail et son procédé de préparation
MY149603A (en) Novel antibiotics, bispolides a1, a2, and a3, as well as bispolides b1, b2a, b2b and b3, and process for producing these antibiotics
WO2012036518A3 (fr) Nouveau composé à activité antibiotique et composition antibiotique comprenant le composé
MY148891A (en) Novel antibiotic, bispolides a1, a2 and a3, and process for poducing the same